Bayer (DE:BAYGN) (BAYRY) closed the most recent trading day at $17.28, moving -0.06% from the previous trading session. This move lagged the S&P 500's daily gain of 0.46%. At the same time, the Dow added 0.15%, and the tech-heavy Nasdaq gained 0.59%.
Coming into today, shares of the drug and chemical company had lost 12.23% in the past month. In that same time, the Medical sector gained 0.72%, while the S&P 500 gained 3.24%.
Wall Street will be looking for positivity from BAYRY as it approaches its next earnings report date. The company is expected to report EPS of $0.47, down 31.88% from the prior-year quarter.
Any recent changes to analyst estimates for BAYRY should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BAYRY currently has a Zacks Rank of #2 (Buy).
Looking at its valuation, BAYRY is holding a Forward P/E ratio of 8.87. Its industry sports an average Forward P/E of 15.37, so we one might conclude that BAYRY is trading at a discount comparatively.
Investors should also note that BAYRY has a PEG ratio of 0.85 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.12 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 111, putting it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Original post